Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
The ongoing QALY debatte was once again focus of a workshop organized by ISPOR in Philadelphia (Nov. 7-8). Proceedings will be posted at the ISPOR webpage in early 2008.
No comments:
Post a Comment